Our study reports on the real-time utility and feasibility of incorporating the evaluation of ctDNA liquid RAS/RAF/EGFR and the status of other relevant resistance mutations in blood in patients with prior anti-EGFR exposure and tissue RAS/RAF-wild-type tumor. The gene discussed is EGFR; the disease is neoplasm.